top of page
Pacific GeneTech Reports Positive Results for its Cross-protective Vaccine Targeting both Salmonella and E. coli in Swine

1 December, 2022

Pacific GeneTech (PGT) reports positive results in a recent trial for its oral Salmonella-based cross-protective vaccine targeting Salmonella in swine.  The study was conducted in US and the same vaccine demonstrated positive results in an earlier trial this year against E. coli (F-18).

The trial compared PGT's vaccine to a leading commercial vaccine against Salmonella Typhimurium. The study used clinical signs and bacteriology as endpoints.

The PGT vaccine performed better than the commercial vaccine positive control following a virulent S. Typhimurium challenge. There was rapid reduction of fecal shedding, improvement of average daily weight gain and the efficacy was numerically better than the commercial product.


The PGT vaccine will be the first vaccine on the market offering cross-protection against both Salmonella and E. coli, which is provided by a single highly conserved antigen common among most Enterobacteriaceae. It is a live attenuated recombinant vaccine based on PGT’s Aegis vaccine platform. PGT is engaged in discussions with commercial partners for licensing the vaccine.


Pacific GeneTech ( develops and commercializes next-generation vaccines and biologics for areas of high unmet or underserved needs in food safety and animal health. PGT's proprietary "Aegis" vaccine platform combines cross-protective antigens and immunopotentiators in PGT vectors for broad spectrum protection against multiple strains and species of infectious diseases. The PGT vaccines can be administered orally or by injection in both live and inactivated forms. PGT's "Hercules" adjuvant/delivery system provides enhanced efficacy of inactivated and its "Argo" yeast vector is a safe, flexible and robust carrier of immunogenic material.


PGT has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development. PGT is developing other applications for its Hercules adjuvant/delivery system and for the Argo vector. PGT, through its affiliate company, PGTx, has commenced programs with collaborators addressing human dysentery.

bottom of page